biostudies-literatureBoers MEuropean Commission925-936https://www.ebi.ac.uk/biostudies/studies/S-EPMC9209692biostudies-literatureUnknown81(7)<h4>Background</h4>Low-dose glucocorticoid (GC) therapy is widely used in rheumatoid arthritis (RA) but the balance of benefit and harm is still unclear.<h4>Methods</h4>The GLORIA (Glucocorticoid LOw-dose in RheumatoId Arthritis) pragmatic double-blind randomised trial compared 2 years of prednisolone, 5 mg/day, to placebo in patients aged 65+ with active RA. We allowed all cotreatments except long-term open label GC and minimised exclusion criteria, tailored to seniors. Benefit outcomes included disease activity (disease activity score; DAS28, coprimary) and joint damage (Sharp/van der Heijde, secondary). The other coprimary outcome was harm, expressed as the proportion of patients with ≥1 adverse event (AE) of special interest. Such events comprised serious events, GC-specific events andAnnals of the rheumatic diseasesLow dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial.PMC9209692Horizon 2020: 634886Allaart CFPinto RCelano ARichards PButtgereit FCosta JRaterman HGCorduta PManger SKlausch LTBos RRuiterman YCutolo MMiddelink LMMolenaar Evan Laar JMFrazao Mateus EBoonen AKlaasen RMarsman AFDoerwald LCodreanu CSieburg Mvan der Heijde DGriep ENMasaryk PDekker VConstantinescu OGLORIA Trial consortiumSilva ISpoorenberg JJacobs JSmulders YMKok MRMendes GBaudoin Pvan den Bulk NElling-Audersch CMicaelo MSchilder AMAanerud GJChristensen RBoers MSzekanecz ZBijlsma JNurmohamed MTTas SWPaolino SOpris-Belinski DBorucki DRusthoven CPrinsen KScholte-Voshaar MSaavedra MJRedol JJansen TLems WFRalston SHBakkers MProthmann UHartman LDa Silva JAfalseLow dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial.<h4>Background</h4>Low-dose glucocorticoid (GC) therapy is widely used in rheumatoid arthritis (RA) but the balance of benefit and harm is still unclear.<h4>Methods</h4>The GLORIA (Glucocorticoid LOw-dose in RheumatoId Arthritis) pragmatic double-blind randomised trial compared 2 years of prednisolone, 5 mg/day, to placebo in patients aged 65+ with active RA. We allowed all cotreatments except long-term open label GC and minimised exclusion criteria, tailored to seniors. Benefit outcomes included disease activity (disease activity score; DAS28, coprimary) and joint damage (Sharp/van der Heijde, secondary). The other coprimary outcome was harm, expressed as the proportion of patients with ≥1 adverse event (AE) of special interest. Such events comprised serious events, GC-specific events and2022-01-01T00:00:00Z2022 Jul2026-06-08T06:49:44.106Z2026-06-08T03:14:11.416ZS-EPMC92096923564112510.1136/annrheumdis-2021-221957